Literature DB >> 19184535

SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis.

Alex Henderson1, F Douglas, P Perros, C Morgan, E R Maher.   

Abstract

Mutations in SDHB are one of the causes of hereditary paraganglioma syndrome. Germline mutations in SDHB predispose to the development of head and neck paragangliomas and phaeochromocytomas. Renal tumours are also increasingly being reported as component tumours in hereditary paragangliomatosis associated with mutations in SDHB. We present the first reported case of a family in whom an individual shown to carry a mutation in SDHB developed a renal oncocytoma. We review other reports of renal tumours associated with SDHB-associated hereditary paragangliomatosis and suggest that various histological subtypes of renal tumours are part of this condition. This observation indicates that SDHB-associated hereditary paragangliomatosis is unlike most tumour predisposition syndromes associated with the development of renal tumours which are usually associated with specific histological sub-types. The increasing recognition of the involvement of renal tumours in SDHB mutation carriers suggests that renal screening is likely to be valuable for these patients. SDHB mutations should also be considered in the context of genetic testing when renal tumours, regardless of histopathology, present in families with other tumours consistent hereditary paraganglioma syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184535     DOI: 10.1007/s10689-009-9234-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  14 in total

Review 1.  Searching for the hereditary causes of renal-cell carcinoma.

Authors:  Christian P Pavlovich; Laura S Schmidt
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.

Authors:  Henri J L M Timmers; Anna Kozupa; Graeme Eisenhofer; Margarita Raygada; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2007-01-02       Impact factor: 5.958

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.

Authors:  Patrick J Pollard; Mona El-Bahrawy; Richard Poulsom; George Elia; Pip Killick; Gavin Kelly; Toby Hunt; Rosemary Jeffery; Pooja Seedhar; Julian Barwell; Farida Latif; Michael J Gleeson; Shirley V Hodgson; Gordon W Stamp; Ian P M Tomlinson; Eamonn R Maher
Journal:  J Clin Endocrinol Metab       Date:  2006-09-05       Impact factor: 5.958

Review 5.  The Heidelberg classification of renal cell tumours.

Authors:  G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar
Journal:  J Pathol       Date:  1997-10       Impact factor: 7.996

6.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

7.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.

Authors:  Stefano J Mandriota; Kevin J Turner; David R Davies; Paul G Murray; Neil V Morgan; Heidi M Sowter; Charles C Wykoff; Eamonn R Maher; Adrian L Harris; Peter J Ratcliffe; Patrick H Maxwell
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

8.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Authors:  Hartmut P H Neumann; Christian Pawlu; Mariola Peczkowska; Birke Bausch; Sarah R McWhinney; Mihaela Muresan; Mary Buchta; Gerlind Franke; Joachim Klisch; Thorsten A Bley; Stefan Hoegerle; Carsten C Boedeker; Giuseppe Opocher; Jörg Schipper; Andrzej Januszewicz; Charis Eng
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

9.  Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers.

Authors:  Umasuthan Srirangalingam; Lisa Walker; Bernard Khoo; Fiona MacDonald; Daphne Gardner; Terence J Wilkin; Robert H Skelly; Emad George; David Spooner; John P Monson; Ashley B Grossman; Scott A Akker; Patrick J Pollard; Nick Plowman; Norbert Avril; Daniel M Berney; Jacky M Burrin; Rodney H Reznek; V K Ajith Kumar; Eamonn R Maher; Shern L Chew
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-14       Impact factor: 3.478

10.  Germline SDHB mutations and familial renal cell carcinoma.

Authors:  Christopher Ricketts; Emma R Woodward; Pip Killick; Mark R Morris; Dewi Astuti; Farida Latif; Eamonn R Maher
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more
  20 in total

Review 1.  Familial pediatric endocrine tumors.

Authors:  Sarinda Millar; Lisa Bradley; Deirdre E Donnelly; Dennis Carson; Patrick J Morrison
Journal:  Oncologist       Date:  2011-09-20

2.  High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants.

Authors:  Ivana Kurelac; Dario de Biase; Claudia Calabrese; Claudio Ceccarelli; Charlotte Ky Ng; Raymond Lim; Alan MacKay; Britta Weigelt; Anna Maria Porcelli; Jorge S Reis-Filho; Giovanni Tallini; Giuseppe Gasparre
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

Review 3.  The genetic basis of kidney cancer: a metabolic disease.

Authors:  W Marston Linehan; Ramaprasad Srinivasan; Laura S Schmidt
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

Review 4.  Advances in the genetics of familial renal cancer.

Authors:  Patrick J Morrison; Deirdre E Donnelly; A Brew Atkinson; Alexander P Maxwell
Journal:  Oncologist       Date:  2010-05-19

Review 5.  The metabolic basis of kidney cancer.

Authors:  W Marston Linehan; Christopher J Ricketts
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

6.  Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome.

Authors:  Victoria M Raymond; Casey M Herron; Thomas J Giordano; Stephen B Gruber
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

Review 7.  Molecular diagnosis and therapy of kidney cancer.

Authors:  W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

8.  [Succinate dehydrogenase (SDH)-deficient renal cell carcinoma].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

9.  Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma.

Authors:  Sean R Williamson; John N Eble; Mahul B Amin; Nilesh S Gupta; Steven C Smith; Lynette M Sholl; Rodolfo Montironi; Michelle S Hirsch; Jason L Hornick
Journal:  Mod Pathol       Date:  2014-07-18       Impact factor: 7.842

10.  Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function.

Authors:  Chunzhang Yang; Joey C Matro; Kristin M Huntoon; Donald Y Ye; Thanh T Huynh; Stephanie M J Fliedner; Jan Breza; Zhengping Zhuang; Karel Pacak
Journal:  FASEB J       Date:  2012-07-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.